Skip to NavigationSkip to content

Donald Trump

How the US election could affect the pharmaceutical industry

Published on 04/11/20 at 01:18pm

The US is one of the most lucrative markets for the pharmaceutical industry. This is a country where a lack of strict price regulation can see companies make record profits, while also getting many of their research and development projects subsidised by the government. It is where Pfizer, Bristol Myers Squibb and Eli Lilly began their businesses, and all notable pharmaceutical companies have a major US presence.

Study that alleges COVID-19 was made in a Chinese lab originated from non-profits linked to ex-Trump advisor Steve Bannon

Photo by Gage Skidmore from Peoria, AZ, United States of America

A new study that alleges COVID-19 was created in a Chinese lab was published by two non-profits that are linked to President Trump’s former chief strategist Steve Bannon, it has emerged.

US reports increase in Hydroxychloroquine misuse

Photo by Joegoauk Goa

The American Association of Poison Control Centers (AAPCC) has said there has been an increase in people abusing the anti-malaria drug hydroxychloroquine, after being touted by President Donald Trump as a coronavirus treatment.

Since Trump first mentioned the drug on 19 March, there have been 76 cases of hydroxychloroquine abuse compared to 35 during this same period last year. 77% of these cases were non-toxic meaning most patients taking the drug inappropriately were not poisoned. 

Donald Trump talks of “retaliation” if India does not export hydroxychloroquine to the US

United States President Donald Trump has suggested that the US may retaliate if India did not export the anti-malaria drug hydroxychloroquine, which is being used to treat COVID-19.

Trump spoke to Prime Minister of India Narendra Modi to convince him to lift a ban on the export of the drug, hours after he enacted the policy.

How do the Presidential frontrunners plan to combat the opioid crisis?

Published on 12/02/20 at 12:58pm

The widespread addiction to extremely potent, legal painkillers has decimated the lives of millions across the United States. Overdoses from opioids have surpassed car crashes and gun violence as the leading cause of death in Americans under the age of 55. The epidemic has killed nearly 400,000 people since 2000 – more people than HIV at the peak of that disease – while its economic cost has been placed between $50 billion and $1 trillion.

Election Day 2019: Where do the two frontrunners stand on the NHS?

The UK goes to the polls today, for the fourth election of the decade and the third since 2015.

Despite the election being initially called by Prime Minister Boris Johnson to break the parliamentary gridlock over Brexit, Labour Party leader Jeremy Corbyn has forced the main electoral issue to centre around the future of the National Health Service. Both have made significantly different proposals for the NHS’s future.

Donald Trump nominates Dr Stephen Hahn as next FDA Commissioner

The US FDA could be set to receive its next long-term Commissioner after the White House revealed President Donald Trump’s top pick to lead the regulatory agency.

Dr Stephen Hahn was announced as the Commander-in-Chief’s nomination for the role. Dr Hahn most recently served as the Chief Medical Executive at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas since May 2018, a patient care organisation employing around 21,000 staff; the firm also generates over $5 billion annually and conducts “the largest number of clinical trials in the United States”.

Donald Trump causes confusion as to whether NHS will be 'on the table' in trade deal talks

President Donald Trump has caused confusion as to whether or not the NHS will ‘be on the table’ in post-Brexit trade deal negotiations with the United States.

Speaking at a press conference on Tuesday, Trump said: “Look I think everything with a trade deal is on the table. When you’re dealing with trade everything is on the table, so NHS, or anything else, or a lot more than that. Everything will be on the table, absolutely.”

Donald Trump says he will not accept campaign money from pharma

President Donald Trump has said he will not accept money from pharmaceutical companies in the run up to the 2020 elections.

Speaking at the Rx Heroin and Drug Abuse Summit in Atlanta, Trump said the industry “should be held accountable” for the role they played in the opioid crisis as he declared that he would not accept campaign contributions from pharma.

“My administration is also taking aggressive action to reduce the oversupply of highly addictive prescription drugs,” Trump said.

Trump ex-lawyer Cohen reveals Novartis pushed him to lobby

Image Credit: Chip Somodevilla/Getty Images

Among the swirling storm emanating from the testimony of Donald Trump’s ex-lawyer Michael Cohen to the House Oversight Committee, one of the many controversial claims to arise is that pharma firm Novartis allegedly attempted to coax him the President’s “fixer” into lobbying government on its behalf.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches